Picture loading failed.

Anti-CSF1R therapeutic antibody (Pre-made Cabiralizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cabiralizumab is developed as a monoclonal antibody antagonist targeted CSF1R, with potential antineoplastic activity. Upon administration, the drug inhibits the binding of CSF1R to CSF1 and interleukin-34 (IL-34) via binding to CSF1R expressed on monocytes, macrophages, and osteoclasts competitively.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-087-1mg 1mg 3090
GMP-Bios-ab-087-10mg 10mg 21890
GMP-Bios-ab-087-100mg 100mg 148000
GMP-Bios-ab-087-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CSF1R therapeutic antibody (Pre-made Cabiralizumab biosimilar,Whole mAb)
INN Name Cabiralizumab
TargetCSF1R
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesApexigen;Bristol-Myers Squibb;Five Prime Therapeutics;University of Chicago;Yale University
Conditions Approvedna
Conditions ActivePancreatic cancer;Pigmented villonodular synovitis;Cancer;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Solid tumours
Conditions DiscontinuedRheumatoid arthritis
Development Techna